Difference between revisions of "Electroconvulsive therapy"

From WikiAnesthesia
m
m
Line 2: Line 2:
#* Seizures induced by ECT are generalized seizures that consist of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.
#* Seizures induced by ECT are generalized seizures that consist of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.
#* Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. If seizure > 120s consider termination with midazolam/propofol.  
#* Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. If seizure > 120s consider termination with midazolam/propofol.  
#* Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure, which requires an appropriate duration of anesthesia & neuromuscular blockade.
#* Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure.
#* Configuration of electrode placement: Left unilateral, Right unilateral, & Bifrontal
#* Configuration of electrode placement: Left unilateral, Right unilateral (most common, fewer memory side effects), & Bifrontal
#** Right unilateral most commonly used to minimize side effects of ECT (ex; short- term cognitive dysfunction)
#* Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression. Total # of treatments determined by  Pt’s clinical response.
#* Both the duration of individual Seizure & cumulative seizure time between treatments correlated with clinical improvement of depression. The total # of treatments determined by  Pt’s clinical response.
#* Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)
#* Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)
# <u>Morbidity and Mortality Rates</u>:<ref name=":0" />
# <u>Morbidity and Mortality Rates</u>:<ref name=":0" />
Line 25: Line 24:
#* Thrombophlebitis
#* Thrombophlebitis
# <u>Physiologic Changes</u>:<ref name=":0" /><ref name=":2" />
# <u>Physiologic Changes</u>:<ref name=":0" /><ref name=":2" />
#* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
#* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
#* ''Cardiovascular''
#* ''Cardiovascular''
#** 1st: Parasympathetic discharge may cause '''asystole''', bradycardia, PVCs, '''hypotension''', & ventricular escape rhythm.
#** 1st: Parasympathetic discharge may cause '''asystole''', bradycardia, PVCs, '''hypotension''', & ventricular escape rhythm.
Line 36: Line 35:
#* ''Neuro'':
#* ''Neuro'':
#** Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & elevated BP -> ↑ ICP
#** Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & elevated BP -> ↑ ICP
#** Preoxygenation prevent cerebral hypoxia.
#* ''Neuroendocrine'':
#* ''Neuroendocrine'':
#** ↑ corticotropin, cortisol, & catecholamines.
#** ↑ corticotropin, cortisol, & catecholamines.
Line 60: Line 58:
# <u>Access</u>: PIV x 1
# <u>Access</u>: PIV x 1
# <u>Management of Induction & Seizure Sequelae</u>: <ref name=":0" /><ref name=":1" /><ref name=":2" />
# <u>Management of Induction & Seizure Sequelae</u>: <ref name=":0" /><ref name=":1" /><ref name=":2" />
## '''Induction''':
##'''Induction''':
##* Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold
##* Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold
##* Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability  
##* Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability  
Line 73: Line 71:
### '''Glycopyrrolate''' 0.2mg to prevent bradycardia. Usually given prior to induction agents
### '''Glycopyrrolate''' 0.2mg to prevent bradycardia. Usually given prior to induction agents
## '''Subsequent Sympathetic discharge''':
## '''Subsequent Sympathetic discharge''':
### Nitroglycerin &/ot Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
### Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
### ''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post
### ''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post
## '''Post-ECT delirium''' (or if flumazenil given Pre-Induction):
## '''Post-ECT delirium''' (or if flumazenil given Pre-Induction):

Revision as of 18:16, 21 August 2021

  1. Background:[1][2]
    • Seizures induced by ECT are generalized seizures that consist of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.
    • Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. If seizure > 120s consider termination with midazolam/propofol.
    • Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure.
    • Configuration of electrode placement: Left unilateral, Right unilateral (most common, fewer memory side effects), & Bifrontal
    • Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression. Total # of treatments determined by Pt’s clinical response.
    • Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)
  2. Morbidity and Mortality Rates:[1]
    • Mortality risk <1 in 75,000 treatments.
    • Most common adverse events: Transient arrhythmias (10%–40%), gastric aspiration (2.5%), & MSK disorders (0.4%), including fractures.
    • Additional adverse events: Pulmonary edema, HA, memory disturbance, & agitation. Very rarely takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.
  3. Indications:[2][3]
    • Refractory Depression (unipolar and bipolar types), Depression with Psychotic features, Catatonia, and schizophrenia
  4. ABSOLUTE Contraindications:[1][3]
    • Untreated Pheochromocytoma
    • Intracranial mass/↑ ICP
    • Recent MI or Stroke w/in last 30 days  
  5. Relative Contraindications:[1]
    • Angina pectoris, CHF
    • COPD
    • Glaucoma, Retinal detachment
    • High-risk pregnancy
    • Severe osteoporosis (fracture risk)
    • Thrombophlebitis
  6. Physiologic Changes:[1][3]
    • ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
    • Cardiovascular
      • 1st: Parasympathetic discharge may cause asystole, bradycardia, PVCs, hypotension, & ventricular escape rhythm.
        • If known profound parasympathetic response, can blunt with a small dose of glycopyrrolate pre-induciton
      • 2nd: Sympathetic tone increases with seizure generation
        • Presents as increased HR, PVCs, bigeminy, trigeminy, sinus tachycardia, ST segment changes (↑ myocardial O2 consumption) & severe HTN.
        • Often resolves quickly, but if Pt requires intervention, consider esmolol or labetalol for tachycardia or HTN
    • Respiratory:
      • During initial parasympathetic discharge at risk for laryngospasm, bronchoconstriction/wheezing
    • Neuro:
      • Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & elevated BP -> ↑ ICP
    • Neuroendocrine:
      • ↑ corticotropin, cortisol, & catecholamines.
      • Effects on glucose levels vary; consider Pre/Post glucose in insulin dependent patients.
    • GI: ↑ intragastric pressure
    • Eye: ↑ intraocular pressure
  7. Pre-Induction Considerations: [1][2][3]
    • Medication Management:
      • Can continue MAO inhibitors, TCAs, SSRIs, & antipsychotics w/ ECT
      • MAO Inhibitors: Avoid ephedrine (indirect-acting sympathomimetics cause exaggerated BP). Be aware they ↓ plasma cholinesterase activity → ↑ succinylcholine duration
      • Lithium – Risk for delayed awakening, memory loss, and postictal confusion. Hold for 12hr before ECT
      • Benzodiazepines – Hold for 12hr before ECT. May need to give flumazenil before ECT to have an adequate seizure duration.
    • Pacemaker vs Implantable Cardioverter-Defibrillator (ICD):
      • Pacemaker
        • If Not dependent on the device, a magnet should be available in event of device failure.
        • If Dependent on pacemaker, program device to asynchronous mode & a backup pacing mode should be available.
      • ICD:
        • Risk that the device misinterprets muscle movements as an abnormal cardiac rhythm and a discharge is possible.
        • Device should be deactivated & an external defibrillator should be immediately available with placement of external defibrillator pads strongly considered.
      • For a patient with an ICD & who is pacemaker dependent, the EP service should be consulted or in any other cases with pacing concerns.
  8. Position: Supine or with HOB elevated
  9. Monitors: Standard ASA monitors with 5 lead ECG. Single lead EEG
  10. Access: PIV x 1
  11. Management of Induction & Seizure Sequelae: [1][2][3]
    1. Induction:
      • Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold
      • Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability
      • Propofol: ↑ seizure threshold & seizure duration. Need higher stimulus voltages to achieve adequate seizure. May be useful in patients with history of long seizures.
      • Ketamine: can cause post-ECT
      • Remifentanil 200-400 mcg as an adjunct to lower dose of methohexital needed; net Sz threshold. Watch out for chest wall rigidity (difficult to mask) give succinylcholine asap if unable to ventilate.
      • Sevoflurane can be used for inhalational induction when no IV access possible.
    2. Paralytic:
      1. Succinylcholine 1- 1.5 mg/kg, titrate to adequate paralysis
      2. Rocuronium - Low dose & only if patient has contraindication to succinylcholine (reverse with sugammadex)
    3. Initial PARAsympathetic discharge:
      1. Glycopyrrolate 0.2mg to prevent bradycardia. Usually given prior to induction agents
    4. Subsequent Sympathetic discharge:
      1. Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
      2. Hyperglycemia often seen in insulin dependent Pt -> BG Pre/Post
    5. Post-ECT delirium (or if flumazenil given Pre-Induction):
      1. Midazolam
  12. General Procedural Steps: [2][3]
    1. Preoxygenate well prior to induction
    2. Once induction medications given & patient unconscious start mask ventilating & give paralytic
    3. Hyperventilate -> Hypocarbia (↓ seizure threshold)
    4. Bite guard placed prior to ECT initiation
    5. After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.
  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller. (2015). Faust's Anesthesiology Review. Print. pp. Anesthesia for Electroconvulsive Therapy, 490–492.CS1 maint: multiple names: authors list (link)
  2. 2.0 2.1 2.2 2.3 2.4 Pardo, Manuel, Ronald D Miller (2017). Basics of Anesthesia 7th Edition. Print. pp. 669–671. ISBN 0323401155.CS1 maint: multiple names: authors list (link)
  3. 3.0 3.1 3.2 3.3 3.4 3.5 ACCRAC (2019-03-13). "Episode 112: Anesthesia for ECT with Christina Miller". ACCRAC Podcast. Retrieved 2021-08-22.